Literature DB >> 20210880

Expression of endothelin-1 and endothelin receptor a in canine ovarian tumours.

G Borzacchiello1, S Mogavero, G Tortorella, G Catone, M Russo.   

Abstract

Ovarian tumours have a low incidence in bitch. Endothelin (ET-1) and endothelin A receptor (ET-A) are overexpressed in human ovarian cancer. Twenty canine ovarian tumours and five normal samples were first evaluated by western blotting and then immunohistochemically for ET-1 and ET-A expression. Seventeen out of twenty tumours were ET-1 positive. Eight out of twenty tumours were ET-A immunohistochemically positive. At molecular level both proteins were proven to be expressed in normal as well as in tumour samples. Our results show that ET-1 and ET-A are overexpressed in canine ovarian tumours, suggesting a potential role of these two molecules in canine ovarian carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20210880     DOI: 10.1111/j.1439-0531.2010.01580.x

Source DB:  PubMed          Journal:  Reprod Domest Anim        ISSN: 0936-6768            Impact factor:   2.005


  3 in total

1.  Activation of ETA Receptor by Endothelin-1 Induces Hepatocellular Carcinoma Cell Migration and Invasion via ERK1/2 and AKT Signaling Pathways.

Authors:  Ning Cong; Zhongmin Li; Wenbo Shao; Jinpeng Li; Shui Yu
Journal:  J Membr Biol       Date:  2015-10-26       Impact factor: 1.843

2.  A dog oviduct-on-a-chip model of serous tubal intraepithelial carcinoma.

Authors:  Marcia de Almeida Monteiro Melo Ferraz; Jennifer Beth Nagashima; Bastien Venzac; Séverine Le Gac; Nucharin Songsasen
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

Review 3.  Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; Shams Tabrez; Nasimudeen R Jabir; V Prakash Reddy; Yi Li; Geoffrey Burnstock; Ramon Cacabelos; Mohammad Amjad Kamal
Journal:  Oxid Med Cell Longev       Date:  2013-04-03       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.